Showing 5011-5020 of 9575 results for "".
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Pinpointing BNP’s Role in ADhttps://practicaldermatology.com/news/pinpointing-bnps-role-in-ad/2462082/The brain natriuretic peptide (BNP) may play a role in activating atopic dermatitis, according to new research in mice. “BNP is expressed in sensory neurons, the neurons responsible for conveying sensation to the brain via the spinal cord,” says Santosh Mishra, associate pro
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers i
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- Almost Half of All Skin Disease Patients Report Sleep Issueshttps://practicaldermatology.com/news/almost-half-of-all-skin-disease-patients-report-sleep-issues/2462075/Almost half of all patients with skin disease report sleep disturbances, finds new research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The ALL PROJECT analyzed data on more than 50,000 adults across 20 countries to assess the impact
- Study: Female Adult Acne Patients Face Stigmahttps://practicaldermatology.com/news/study-female-adult-acne-patients-face-stigma/2462073/Faces with acne are seen as less attractive, trustworthy, confident, successful, dominant and happy, and adult female acne has the strongest negative effect, according to research presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The
- AI in Action: Newest AI Boasts 100% Success Rate in Spotting Melanomashttps://practicaldermatology.com/news/newest-ai-boasts-100-success-rate-in-spotting-melanomas/2462072/The latest artificial intelligence (AI) software reached a 100% detection rate for melanoma, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin. The study assessed 22,356 patients with suspected skin cancers over a 2.5-year p
- Delgocitinib Cream Soothes Moderate to Severe Chronic Hand Eczemahttps://practicaldermatology.com/news/delgocitinib-cream-soothes-moderate-to-severe-chronic-hand-eczema/2462071/Delgocitinib cream produced statistically significant improvements in both patient- and clinician-reported efficacy outcomes in adults with moderate to severe chronic hand eczema (CHE) compared to cream vehicle, according to results from the DELTA 2 trial presented at the European Academy of Derm
- Tralokinumab Controls AD Over the Long Termhttps://practicaldermatology.com/news/adtralza-tralokinumab-controls-ad-over-the-long-term/2462069/Continuous use of Leo Pharma’s Adtralza (tralokinumab) provided long-term disease control in adult patients with moderate-to-severe atopic dermatitis (AD), according to a post hoc, interim, subgroup analysis of the ongoing ECZTEND study presented at the European Academy of Dermatology and V
- Roflumilast Foam 0.3% Eases Scalp Itch in as Early as 24 hourshttps://practicaldermatology.com/news/roflumilast-foam-03-eases-scalp-itch-in-as-early-as-24-hours/2462068/Arcutis’ roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis across all efficacy endpoints when compared to vehicle, according to patient-reported outcome data from the pivotal ARRECTOR Phase 3 trial in scalp and body psoriasis presented at the